BY PHILIP MADSEN
-
Major shake-up in Coloplast’s senior management: Two group directors out
Coloplast has actually discovered a brand-new long-term supervisor for its urology company and has actually started the look for a human resources supervisor.
-
Report: US doctors prefer Novo Nordisk’s weight loss tablet
According to an evaluation, most of family doctors in the United States would certainly favor to suggest Novo Nordisk’s upcoming weight management tablet computer over comple…
-
DBV Technologies receive positive results in key study with peanut patch
Biotech business DBV Technologies will certainly look for authorization from the United States authorities in the very first fifty percent of 2026.
-
Medline completes largest IPO of the year
With the stock market listing, the US medical device company is valued at USD 39bn.
-
Johnson & Johnson granted US priority review for combination treatment with Genmab drug
The United States pharmaceutical titan is established for faster regulative testimonial of its mix treatment including Genmab’s Darzalex.
-
Goldman Sachs: New trends add extra value to weight loss market
United States rates contracts, tablet computers, and even more consumerization of the markget for weight-loss medications will certainly include USD billions to the marketplace wor…
-
Danske Bank proposes former CEO for Bavarian Nordic board
Anders Hedegaard, Chief Executive Officer of Bavarian Nordic from 2007 to 2014, will certainly not make a decision for himself whether he is an appropriate prospect.
-
Former Coloplast CEO becomes chair and co-owner of Danish health tech-startup
After leaving Coloplast in May, Villumsen has actually started a profession as a board participant and financier.
-
Pfizer lays off more than 200 employees in Switzerland
This is an outcome of a worldwide cost-cutting program that has actually additionally impacted Pfizer in Denmark and Norway.
-
Shareholders approve Demant chairman as new board member at Coloplast
Coloplast’s longest-serving board participant, Lars Rasmussen, is tipping down from the board as intended, while the remainder of the board will certainly proceed.